![CJC-1295 WITH DAC [5mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/cjc-dac.jpg)
$90.00
CJC-1295 with DAC is a long-acting synthetic GHRH analog studied for sustained growth-hormone and IGF-1 signaling. Evidence for long-term benefits in healthy adults is limited. This 5 mg research vial is not an FDA-approved medicine.
For laboratory research only. Not for human or animal consumption.
VIP Peptides · Research Compound
CJC-1295 with DAC is a long-acting synthetic analog of growth
hormone-releasing hormone (GHRH). Its Drug Affinity Complex (DAC) is
designed to bind to serum albumin and extend its activity. This profile
covers the 5 mg research vial.
Product Information
The DAC modification is intended to extend the peptide’s activity
through albumin binding. The supplied source describes an approximate
half-life of 6–8 days and a sustained effect on growth-hormone (GH)
and IGF-1 levels.
This differs from CJC-1295 without DAC (Modified GRF 1-29), which is
short-acting. The two forms should not be treated as interchangeable.
Sustained changes in GH or IGF-1 do not, by themselves, establish
health or performance benefits.
| Product | CJC-1295 with DAC |
|---|---|
| Compound type | Long-acting GHRH analog |
| Vial quantity | 5 mg |
| Research focus | GH and IGF-1 signaling |
| Compared with | Short-acting CJC-1295 without DAC |
| Regulatory status | Not FDA-approved for any indication |
Research Areas
Human studies have examined dose-related and sustained changes in
GH and IGF-1 after CJC-1295 exposure. These hormone-level changes do
not prove improvements in health, body composition or physical
performance.
GH and IGF-1 pathways are studied in relation to fat metabolism and
lean tissue. Reliable long-term body-composition benefits in healthy
adults have not been established.
Sleep quality, recovery and connective-tissue effects are discussed
as possible outcomes of prolonged GH signaling. Strong clinical
evidence establishing these benefits for CJC-1295 with DAC is
limited.
Albumin binding is intended to extend activity and reduce the need
for frequent administration compared with short-acting GHRH
analogs. A longer duration does not establish greater safety or
clinical effectiveness.
Evidence Limitations
Human research has examined hormone-level changes, but long-term
outcomes in healthy adults remain limited. Claims about fat loss,
lean-mass gains, sleep, recovery and connective-tissue health should
not be presented as proven effects.
Sustained GH and IGF-1 elevation differs from a short, pulsatile
signal. The long-term effects and the possibility of adverse effects
from ongoing hormonal changes are not fully established.
Safety & Regulatory Status
CJC-1295 with DAC is not FDA-approved for any indication. The FDA notes
limited clinical safety data and potential concerns involving
immunogenicity and peptide-related impurities in compounded CJC-1295
products. The FDA also reports serious adverse events associated with
CJC-1295, including increased heart rate and systemic vasodilatory
reactions.
Reported effects in the supplied source include injection-site
reactions, flushing, water retention, bloating, increased hunger,
joint stiffness, headache and temporary numbness or tingling. The
available information does not establish long-term safety.
CJC-1295 is prohibited under the WADA Prohibited List as a
growth-hormone-releasing factor. The list applies in- and
out-of-competition.
Age & Policy Confirmation
Please confirm your age and review the policies before entering.
![KPV (Lysine-Proline-Valine) [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/kpv-300x300.jpg)
![FOXO4 (Proxofim) [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/fox-300x300.jpg)
![Epitalon [50mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/epitalon-1-300x300.jpg)
Reviews
There are no reviews yet.